# Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

> **NCT02415608** · PHASE2 · TERMINATED · sponsor: **Jason Robert Gotlib** · enrollment: 4 (actual)

## Conditions studied

- Aggressive Systemic Mastocytosis
- Mast Cell Leukemia
- Systemic Mastocytosis

## Interventions

- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT02415608
- **Lead sponsor:** Jason Robert Gotlib
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03
- **Primary completion:** 2016-11-04
- **Final completion:** 2017-06-14
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2018-09-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02415608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02415608, "Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02415608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*